Ryzneuta (Efbemalenograstim alfa)

Inquire / Price
  • Model Number:
    RL23202402
  • Brand Name:
    Ryzneuta (亿立舒)
  • Origin:
    Original invention from China
  • Small Orders:
    Small batches also available
  • Tags:
Inquire Now Link

Poster
  • Details
  • Description
  • Packaging Size
    1vial/Box
  • Strength
    20mg/1ml
  • Compositon
    Efbemalenograstim alfa (艾贝格司亭-α)
  • Treatment
    chemotherapy-induced neutropenia (CIN)
  • Form
    Injection
  • Brand
    Ryzneuta (亿立舒)
  • Quantity Unit
    20mg/1ml*1vail/Box
  • Manufacturer
    Evive Biotech,china

Ryzneuta® (Efbemalenograstim alfa-vuxw), sold under the brand name 亿立舒® in china, is a leukocyte growth factor used for reducing the incidence of infection, as manifested by febrile neutropenia (FN), in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer medicines associated with a clinically significant incidence of febrile neutropenia (FN). 

It was approved for medical use in China in May 2023, and the United States in November 2023.

November 16, 2023 – The FDA approved Evive Biotechnology’s Ryzneuta (efbemalenograstim alfa-vuxw), to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.


Link

Poster

Top